New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
09:25 EDTCYTX, ALXA, ZQK, ADBE, BV, BBYOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Adobe (ADBE), up 5.7%... ALSO HIGHER: Alexa Pharmaceuticals (ALXA), up 21.4% after approval granted in EU for Adasuve... Bazaarvoice (BV), up 7.4% after upgrade to Outperform at Credit Suisse... LOWER AFTER EARNINGS: Quiksilver (ZQK), down 14%... Verifone (PAY), down 7.6%... ALSO LOWER: Best Buy (BBY), down 10.8% after board extends deadline for bid from founder Schulze... Cytori Therapeutics (CYTX), down 15% after 7M share secondary stock offering.
News For BBY;ADBE;ALXA;BV;ZQK;CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:07 EDTCYTXCytori to present two year Scleroderma data at Systemic Sclerosis World Congress
Subscribe for More Information
05:06 EDTADBEAdobe implied volatility of 50 at upper end of index mean range
Subscribe for More Information
February 9, 2016
09:04 EDTBVBazaarvoice announces strategic partnership with BzzAgent
Subscribe for More Information
February 8, 2016
07:01 EDTCYTXCytori Therapeutics reports interim data on U.S. Phase II osteoarthritis trial
Cytori Therapeutics announced the top-line data as part of the pre-specified partial unblinding of 24 week follow up data from the company's ACT-OA trial. The trial is a U.S. phase II randomized, double-blind, placebo controlled trial designed to evaluate the safety and feasibility at 48 weeks of a single intra-articular knee injection of the ECCO-50 cellular therapeutic in patients with chronic knee pain due to osteoarthritis. "Key endpoints and trends observed thus far suggest that a beneficial effect may be attributable to a single intra-articular administration of ECCO-50 in patients with osteoarthritis of the knee," said Dr. Marc H. Hedrick, President and CEO. "The full 48 week data set is the next important milestone in this program. While we continue to move our clinical pipeline along, the company will remain intensely focused on bringing to market our lead therapeutic for scleroderma which is currently in phase III." The primary goal of the ACT-OA trial is to help determine: (1) safety and feasibility of ECCO-50 for osteoarthritis, (2) provide dosing guidance and (3) explore key trial endpoints useful for a phase III trial. As a proof of concept trial, ACT-OA was not sized or powered for statistical significance in any of the endpoints. The purpose of the interim 24 week partial unblinding in this trial is to provide early data that will facilitate key regulatory and business development discussions and provide better understanding of the therapeutic mechanism of action that may impact other clinical programs. The interim analysis pre-specifies the evaluation of a number of patient reported outcomes important in patients with osteoarthritis of the knee. A total of 94 patients were treated in the trial, 31 received a high dose of ECCO-50. Patients, providers and Cytori personnel remain blinded to individual patient treatment allocation and patient subgroup outcomes.
05:27 EDTADBEStocks with implied volatility movement; ADBE SBUX
Subscribe for More Information
February 5, 2016
12:26 EDTADBEOptions with increasing implied volatility
Subscribe for More Information
February 3, 2016
07:15 EDTCYTXCytori says Cytori Cell Therapy 'safe' and 'effective' in EU Phase 1 ED trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use